Pfizer Delays Generic Vyndamax Until 2031 – Great News for BridgeBio’s Attruby
Pfizer extends Vyndamax patent to 2031, delaying generics and giving BridgeBio more time to grow its rival heart drug without pressure.
Pfizer extends Vyndamax patent to 2031, delaying generics and giving BridgeBio more time to grow its rival heart drug without pressure.
Pfizer and Valneva reported their Lyme disease vaccine demonstrated 73.2% efficacy in the Phase 3 VALOR trial. While it missed the primary statistical target due to fewer cases, strong results support upcoming regulatory submissions.
BioNTech co-founders Ugur Sahin & Özlem Türeci are starting an independent next-gen mRNA company by end-2026. BioNTech keeps focus on oncology (15 Phase 3 trials).
JPMorgan & William Blair raise BridgeBio price targets to $93–$94 on strong Attruby launch and achondroplasia data.
Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.
Novavax reports strong 2025 results, first Q4 profit in years, and boosts 2026 outlook thanks to Pfizer & Sanofi deals.